Thrombotic Microangiopathy After Kidney Transplantation
Author Information
Author(s): Ittai Fattal, Tali Steinmetz, Natalie Donin, Ana Foigelman Tobar, Benaya Rozen-Zvi, Ruth Rahamimov, Eviatar Nesher, Idit Shirazi, Eytan Mor, Ilan Babai, Zvi Fishelson
Primary Institution: Rabin Medical Center—Beilinson Hospital
Hypothesis
What are the risk factors and prognosis for thrombotic microangiopathy following renal transplantation?
Conclusion
Thrombotic microangiopathy is associated with various risk factors beyond calcineurin inhibitor exposure, and early-onset cases managed with eculizumab show better outcomes.
Supporting Evidence
- 69% of patients had potential risk factors for thrombotic microangiopathy other than calcineurin inhibitors.
- 46% of patients required dialysis within 2 years due to graft failure.
- Three patients with early-onset thrombotic microangiopathy improved under eculizumab treatment.
Takeaway
This study looked at patients who had problems after kidney transplants. Some got better with a special medicine, but many had serious issues.
Methodology
Clinical and laboratory data were collected retrospectively from 13 patients diagnosed with post-transplant thrombotic microangiopathy.
Limitations
The study had a small sample size and was conducted at a single center.
Participant Demographics
The cohort included 8 females and 5 males with a mean age of 41 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website